PEGBIO CO-B (02565) announced that it recently received a notice from its cornerstone investor, Benefit Kangrui Pharmaceuticals (Hong Kong) Limited, agreeing not to reduce any holdings of the company's H-shares in any manner from the original lock-up expiration date until December 31, 2025 (extended lock-up period). The company believes this extension demonstrates the cornerstone investor's confidence in PEGBIO CO-B's future prospects, based on its R&D capabilities in advancing technology and significant progress in key clinical milestones. The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones.